Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cybin Inc. Common Shares (NY:CYBN)

7.350 -0.100 (-1.34%)
Official Closing Price Updated: 8:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
39 40 Next >
Psychedelic Stock Gainers And Losers From February 14, 2022
GAINERS: Wellbeing Digital (OTC: 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Working on Turning Psychedelics-to-Therapeutics(TM) Vision into Reality
Via Investor Brand Network
Cybin, MindMed, And Field Trip Health Headline PSYC's First CEO Round Table Event
Media company Global Trac Solutions, Inc. (OTCP:PSYC) and authorities behind psychedelic news and information platform Psy... 
Via Benzinga
Psyched: Cathie Wood Invests In Psychedelics Co ATAI, Bill Approved in Utah, AI Startup To 'Design States Of Mind'
The psychedelics sector received its latest sign of acceptance from Wall Street with famed investor Cathie Wood taking a position ... 
Via Benzinga
Earnings Scheduled For February 10, 2022
Companies Reporting Before The Bell • Canada Goose Hldgs (NYSE:GOOS) is projected to report quarterly earnings at $1.46 per share on revenue of $584.49 million. 
Via Benzinga
Mind Medicine, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC: RVVTF) shares closed up 2.51% at $0.22 LOSERS: Mind Medicine (NASDAQ: MNMD) shares closed down 8.09% at $1.25 Cybin (AMEX:CYBN) shares closed down 6.25% at $1.05 ATAI... 
Via Benzinga
Allied, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Allied (OTC:ALID) shares closed up 7.39% at $1.89 
Via Benzinga
Cybin Granted US Patent Covering Lead Proprietary Compound
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Cybin (NEO: CYBN) (NYSE American: CYBN) Granted US Patent Covering Lead Proprietary Compound
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Psychedelic Stock Gainers And Losers From February 9, 2022
GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 14.29% at $5.76 
Via Benzinga
Benzinga's Unprecedented Psychedelics Investing Conference Lands In Miami On April 19th
The first Benzinga Psychedelics Capital Conference, the premier gathering of psychedelics industry leaders and forward-thinking investors, is coming to the Fontainebleau Miami Beach on April 19, 2022,... 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Granted US Patent Covering Lead Proprietary Compound for Treatment of Anxiety Disorders
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Obtains U.S. Patent For Is Proprietary Compound Deuterated DMT Aimed At Treating Anxiety Disorders
Psychedelics company Cybin Inc. (NEO:CYBN) (AMEX:CYBN) announced that the U.S. Patent and Trademark Office  has granted U.S. patent 11,242,318 to the company’s investigational deuterated... 
Via Benzinga
Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders
From Cybin Inc.
Via Business Wire
Mindset Pharma, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Awakn Life Sciences (OTC:AWKNF) shares closed up 3.51% at $1.62 
Via Benzinga
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 9.82% at $1.23 
Via Benzinga
Cybin Marks 2021 Accomplishments, Eyes 'Transformative' 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Cybin (NYSE American: CYBN) (NEO: CYBN) Marks 2021 Accomplishments, Eyes ‘Transformative’ 2022
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Psyched: Psychedelics ETF Launches On NYSE, Psilocybin Trial Approved For Depression, DMT Study Begins
This week saw new triumphs for public companies in the psychedelics space with the creation of a new ETF tracking the sector, which went public in the NYSE. 
Via Benzinga
Psychedelic Stocks Finally In An Upswing
The Marijuana & Psychedelic Compounds-Based Drug Stocks Index went up +5.3% last week. 
Via Talk Markets
Small Pharma, Mind Medicine Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 7.29% at $0.20 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Marks Major Accomplishments in 2021, Eyes ‘Truly Transformative’ 2022
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Field Trip Health, Seelos Therapeutics Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 6.29% at $0.19 
Via Benzinga
Mind Medicine, Allied Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 5.04% at $0.17 
Via Benzinga
Mindset Pharma, Allied Among Top Psychedelic Movers Of Today
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 15.70% at $0.69 
Via Benzinga
Cybin's IRB-Approved Study Begins Enrollment This Year
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Upcoming study supports CYBN’s mission to develop psychedelics... 
Via Benzinga
Cybin’s (NEO: CYBN) (NYSE American: CYBN) IRB-Approved Study Begins Enrollment This Year
Via Investor Brand Network
Magic Mushrooms For Depression: Clinical Trial Of Active Compound Approved For Patients Using Antidepressants
Health Canada has allowed a phase 2 clinical trial of psilocybin in patients currently undergoing treatment with traditional antidepressants. 
Via Benzinga
ATAI Life Sciences, Mind Medicine Among Top Psychedelic Movers Of Today
GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 7.89% at $5.33 
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.